Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
NCT03815396Phase 1Completed
- Sponsor
- Inhibrx Biosciences
- Start
- Jul 2019
- Primary completion
- Aug 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, open-label trial of efdoralprin alfa in alpha-1 antitrypsin deficiency (AATD) (2 arms), sponsored by Inhibrx Biosciences. Primary endpoints: Frequency of adverse events of INBRX-101 up to 7 months and Severity of adverse events of INBRX-101 up to 7 months. Started Jul 2019; status: completed.
02
Drugs
efdoralprin alfa
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT03815396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815396.